Sonoma Pharmaceuticals, Inc. (SNOA) Stock

Sonoma Pharmaceuticals, Inc. (SNOA) is a Healthcare stock trading at $1.18 (as of 2026-06-18), with a market capitalization of $4.86M and a trailing P/E of -0.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid (HOCl) products used in wound care, animal health, eye care, oral care, and dermatological conditions. Its product lines include prescription and non-prescription HOCl therapies such as Epicyn, Levicyn, Celacyn, SebuDerm, Acuicyn, and Microcyn for use by customers in the United States, Latin America, Europe, and other international markets.

Valuation — source: SEC EDGAR (first-party)
Price	$1.18
Market Cap	$4.86M
P/E Ratio	-0.6
EV / EBITDA	0.2
Price / Book	0.57
Price / Sales	0.11
DCF Value (model)	$1.40
DCF Upside vs Price	18.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$14.29M
Net Margin	-24.2%
Return on Equity	-98.2%
Current Ratio	2.88
Revenue Growth (YoY)	22.0%
EPS Growth (YoY)	-23.8%
FCF Growth (YoY)	13657.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-19.20 (distress)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-0.6
Sector P/E (Healthcare)	20.9
Industry P/E (Medical Equipment)	31.7
vs Sector	-102.8%
vs Industry	-101.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($68749.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Amy Trombly
Employees	10
Country	US
IPO Date	2007-01-25

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.